News
Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...
Trump administration demands lower prices in the U.S., forcing the pharmaceutical company to raise them in other markets ...
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.
This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
StockStory.org on MSN2d
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...
Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results